




## EDITORIAL

# JEM goes viral

Carl F. Nathan<sup>1</sup>, Michel C. Nussenzweig<sup>1</sup>, and Teodoro Pulvirenti<sup>2</sup>

Viral pathogens continue to put people's lives at risk, from Ebola to Zika, dengue, Chikungunya, influenza, HIV, and more. While prominent progress has been made to treat HIV infection and reduce its spread, HIV and many other viruses, including influenza, remain a major menace. In the midst of the search for new vaccines (see Rappuoli et al. 2019. *J. Exp. Med.* <https://doi.org/10.1084/jem.20182160>) and treatments and faced with counterproductive anti-vaccination movements, we believe it is more important than ever for *JEM* to emphasize the journal's interest in studies related to viral infection and to microbiology in general. With this intention, we welcome Sara Cherry to the *JEM* editorial board.

Sara Cherry is a Professor in the Department of Pathology and Laboratory Medicine and the Department of Biochemistry

and Biophysics, Scientific Director of the High-throughput Screening Core, and Director of the Chemogenomic Discovery Program in the School of Medicine at the University of Pennsylvania. She obtained her BS with Dr. Peter Schultz at Berkeley synthesizing new biopolymers for drug scaffolds, and then her PhD with Dr. David Baltimore at MIT studying early B cell development. Dr. Cherry completed her postdoctoral fellowship with Dr. Norbert Perrimon, with whom she developed high-throughput RNAi screening to study virus-host interactions. She started her laboratory at Penn in 2006, where she has applied cell-based screening approaches to discover mechanisms by which diverse viral pathogens hijack cellular machinery while evading innate immune defenses.



### Sara Cherry

Sara Cherry is a Professor in the Department of Pathology and Laboratory Medicine and the Department of Biochemistry and Biophysics, Scientific Director of the High-throughput Screening Core and Director of the Chemogenomic Discovery Program in the School of Medicine at the University of Pennsylvania. She obtained her BS with Dr. Peter Schultz at Berkeley synthesizing new biopolymers for drug scaffolds, and then her PhD with Dr. David Baltimore at MIT studying early B cell development. Next, she completed her postdoctoral fellowship with Dr. Norbert Perrimon, where she developed high-throughput RNAi screening to study virus-host interactions. She started her laboratory at Penn in 2006, where she has applied cell-based screening approaches to discover mechanisms by which diverse viral pathogens hijack cellular machinery while evading innate immune defenses.

<sup>1</sup>Editorial Board Co-Chair, *Journal of Experimental Medicine*; <sup>2</sup>Executive Editor, *Journal of Experimental Medicine*.

[tpulvirent@rockefeller.edu](mailto:tpulvirent@rockefeller.edu).

© 2020 Nathan et al. This article is distributed under the terms of an Attribution-Noncommercial-Share Alike-No Mirror Sites license for the first six months after the publication date (see <http://www.rupress.org/terms/>). After six months it is available under a Creative Commons License (Attribution-Noncommercial-Share Alike 4.0 International license, as described at <https://creativecommons.org/licenses/by-nc-sa/4.0/>).